Drug intelligence / Profile preview

GCF20212

Development stage: Preclinical
Lead developer: Guangzhou Green Cross Pharmaceutical
Modality: Small Molecules
Administration: Intravenous

Overview

GCF20212 (also known as GCA2012) is an innovative small molecule drug candidate developed by Guangzhou Green Cross Pharmaceutical. It is formulated using lipid microsphere technology, a specialized drug delivery system designed to improve the stability and pharmacokinetic profile of the active ingredient. The drug is specifically intended for perioperative blood pressure maintenance and the support of patients with critical or serious illnesses during the perioperative period. As of early 2024, GCF20212 is in the IND-enabling stage of development in China, categorized under the cardiovascular and cerebrovascular therapeutic area.

Beyond the preview

Go deeper on GCF20212.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GCF20212.

Explore the full profile